No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BHVN240621C40000
- 0.20
- +0.10+100.00%
15min DelayClose Jun 14 15:59 ET
0.24High0.20Low
0.20Open0.10Pre Close165 Volume3.78K Open Interest40.00Strike Price3.40KTurnover99.71%IV18.83%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.1116Delta0.0432Gamma150.36Leverage Ratio-0.0657Theta0.0006Rho16.78Eff Leverage0.0084Vega
Intraday
- 5D
- 1D
News
Express News | NYSE Order Imbalance 50369.0 Shares on Buy Side
Biohaven Insider Bought Shares Worth $996,240, According to a Recent SEC Filing
John W Childs, Director, on May 30, 2024, executed a purchase for 28,000 shares in Biohaven (BHVN) for $996,240. Following the Form 4 filing with the SEC, Childs has control over a total of 6,432,244
Biohaven(BHVN.US) Director Buys US$996.24K in Common Stock
$Biohaven(BHVN.US)$ Director CHILDS JOHN W purchased 28,000 shares of common stock on May 30, 2024 at an average price of $35.58 for a total value of $996.24K.Source: Announcement What is statement of
Buy Rating Affirmed for Biohaven Ltd. Amidst Expansion and Progress in R&D Programs
Express News | HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target
Express News | Cantor Fitzgerald Reiterates Overweight on Biohaven
Comments
» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings(CERE.US$
$Amicus Therapeutics(FOLD.US$
$Iovance Biotherapeutics(IOVA.US$
$Arcellx(ACLX.US$
$Nuvalent(NUVL.US$
$Apogee Therapeutics(APGE.US$
$Inhibrx(INBX.US$
$Fusion Pharmaceuticals(FUSN.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Vaxcyte(PCVX.US$
$Soleno Therapeutics(SLNO.US$
$Medtronic(MDT.US$
$Madrigal Pharmaceuticals(MDGL.US$
...
7
$Biohaven(BHVN.US$ its killing me
it's number 4, $Amylyx Pharmaceuticals(AMLX.US$ all time low 6.5 USD... hope you can grow and get all FDA approval... it's profitable already...
no 1. $Biogen(BIIB.US$ all time low 2 USD
no 2. $Neurocrine Biosciences(NBIX.US$ all time low 1.9 USD
no 3. $Biohaven(BHVN.US$ all time low 7 USD
no5. $argenx SE(ARGX.US$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...
no 1. $Biogen(BIIB.US$ all time low 2 USD
no 2. $Neurocrine Biosciences(NBIX.US$ all time low 1.9 USD
no 3. $Biohaven(BHVN.US$ all time low 7 USD
no5. $argenx SE(ARGX.US$ all time low 17 USD
And it's not bubble. Of course there are also, biotech companies which are failed. But I think if it's growing into a right directio...
2
$Biohaven(BHVN.US$ buying at bid at 43ish over valued
Compared to the success of $Eli Lilly and Co(LLY.US$ and $NOVO NORDISK A/S(NONOF.US$, $Pfizer(PFE.US$ had a rocky start in launching its weight-loss pill. Last December, Pfizer announced that it would discontinue the development of a twice-daily iteration of its weight loss medication danuglipron, due to its unacceptable side effect profile as revealed by a Phase 2b trial. Before that, Pfizer gave up an oral dr...
+3
11
Read more